Relapsing Multiple Sclerosis - Pipeline Review - H1 2015

Published: April 2015



Global Markets Direct’s, ‘Relapsing Multiple Sclerosis (RMS) - Pipeline Review, H1 2015’, provides an overview of the Relapsing Multiple Sclerosis (RMS)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Relapsing Multiple Sclerosis (RMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Multiple Sclerosis (RMS) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. 



  • The report provides a snapshot of the global therapeutic landscape of Relapsing Multiple Sclerosis (RMS)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Relapsing Multiple Sclerosis (RMS) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Relapsing Multiple Sclerosis (RMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Relapsing Multiple Sclerosis (RMS) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to Buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Relapsing Multiple Sclerosis (RMS)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Relapsing Multiple Sclerosis (RMS) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Table of Contents
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Relapsing Multiple Sclerosis (RMS) Overview 7
Therapeutics Development 8
Pipeline Products for Relapsing Multiple Sclerosis (RMS) - Overview 8
Pipeline Products for Relapsing Multiple Sclerosis (RMS) - Comparative Analysis 9
Relapsing Multiple Sclerosis (RMS) - Therapeutics under Development by Companies 10
Relapsing Multiple Sclerosis (RMS) - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Relapsing Multiple Sclerosis (RMS) - Products under Development by Companies 14
Relapsing Multiple Sclerosis (RMS) - Companies Involved in Therapeutics Development 15
Cognosci, Inc. 16
F. Hoffmann-La Roche Ltd. 17
Genzyme Corporation 18
Mallinckrodt plc 19
Receptos, Inc. 20
Teva Pharmaceutical Industries Limited 21
Relapsing Multiple Sclerosis (RMS) - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
COG-133 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
corticotropin - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
DC-TAB - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
glatiramer acetate - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
GZ-402668 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
interferon beta-1a - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
ocrelizumab - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ozanimod - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
peginterferon beta 1a - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Relapsing Multiple Sclerosis (RMS) - Recent Pipeline Updates 45
Relapsing Multiple Sclerosis (RMS) - Dormant Projects 52
Relapsing Multiple Sclerosis (RMS) - Discontinued Products 53
Relapsing Multiple Sclerosis (RMS) - Product Development Milestones 54
Featured News & Press Releases 54
Apr 13, 2015: Teva to Present Multiple Sclerosis Data at 67th American Academy of Neurology Annual Meeting in Washington, D.C. 54
Dec 22, 2014: Receptos Initiates SUNBEAM Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis 54
Dec 04, 2014: Teva Receives Positive Outcome in Europe for Three-Times-a-Week COPAXONE (Glatiramer Acetate) 40 mg/ml for the Treatment of Relapsing Forms of Multiple Sclerosis (RMS) 55
Jun 09, 2014: Receptos Reports Positive Phase 2 Results for RPC1063 in Relapsing Multiple Sclerosis 56
Jan 06, 2014: Receptos Begins Enrollment of Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis 56
Oct 03, 2013: Teva to Present Further Results of Twenty-Year Open-Label Extension Study of Glatiramer Acetate 20 mg Daily for Relapsing-Remitting Multiple Sclerosis 57
Jun 05, 2013: Receptos Provides Update On Progress Of Lead Product Candidate RPC1063 57
May 30, 2013: Teva Announces FDA Acceptance Of sNDA For Higher Concentration Dose Of Copaxone 59
Jun 25, 2012: Natco Pharma To Appeal US Court Ruling On Copaxone 59
Jan 17, 2012: Genentech Recruits Investigators For Two Phase III Studies Comparing Ocrelizumab To Rebif In People With Relapsing Multiple Sclerosis 59
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 61
Disclaimer 62